Spruce Street Capital LP increased its position in shares of Savara Inc. (NASDAQ:SVRA – Free Report) by 40.3% in the 1st quarter, HoldingsChannel.com reports. The firm owned 3,383,175 shares of the company’s stock after acquiring an additional 972,082 shares during the period. Savara accounts for 4.5% of Spruce Street Capital LP’s holdings, making the stock its 8th biggest position. Spruce Street Capital LP’s holdings in Savara were worth $18,472,000 at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in Savara by 48.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock valued at $60,000 after purchasing an additional 3,205 shares during the last quarter. Principal Financial Group Inc. purchased a new position in shares of Savara in the first quarter valued at $57,000. Russell Investments Group Ltd. raised its stake in shares of Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after buying an additional 9,463 shares during the last quarter. Xponance LLC acquired a new position in shares of Savara during the 4th quarter worth $66,000. Finally, CIBC Bancorp USA Inc. acquired a new position in shares of Savara during the 3rd quarter worth $44,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
SVRA has been the topic of a number of research reports. Oppenheimer initiated coverage on shares of Savara in a research note on Friday, April 24th. They issued an “outperform” rating and a $11.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a report on Friday, July 17th. Finally, Wall Street Zen upgraded shares of Savara from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $10.14.
Savara Stock Performance
Savara stock opened at $5.51 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.47 and a current ratio of 13.47. The stock has a fifty day moving average of $5.53 and a two-hundred day moving average of $5.52. The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of -9.84 and a beta of 0.24. Savara Inc. has a fifty-two week low of $2.43 and a fifty-two week high of $7.01.
Savara (NASDAQ:SVRA – Get Free Report) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). On average, analysts anticipate that Savara Inc. will post -0.57 EPS for the current fiscal year.
Savara Profile
Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.
The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.
Recommended Stories
- Five stocks we like better than Savara
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Want to see what other hedge funds are holding SVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Savara Inc. (NASDAQ:SVRA – Free Report).
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.
